Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.35 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.35 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.34 |
| ▸ | DTYMK | P23919 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24823140 | 1.00 | P2RX3 (0.36) | P2RX3P2RX1P2RX2P2RX4ENTPD1 | |
| SCHEMBL23734491 | 0.93 | ENTPD1 (0.36) | P2RX3P2RX1P2RX2P2RX4ENTPD1 | |
| SCHEMBL23734525 | 0.93 | P2RX3 (0.37) | P2RX3P2RX1P2RX2P2RX4ENTPD1 | |
| SCHEMBL24823762 | 0.93 | P2RX3 (0.37) | P2RX3P2RX1P2RX2P2RX4ENTPD1 | |
| SCHEMBL23734355 | 0.92 | P2RX3 (0.35) | P2RX3P2RX1P2RX2P2RX4ENTPD1 | |
| SCHEMBL23734524 | 0.91 | POLB (0.35) | P2RX3P2RX1P2RX2P2RX4ENTPD1 | |
| SCHEMBL24906065 | 0.91 | POLB (0.34) | P2RX3P2RX1P2RX4DTYMKPOLB | |
| SCHEMBL23734288 | 0.88 | POLG (0.40) | P2RX3P2RX1P2RX4POLB | |
| SCHEMBL24822985 | 0.88 | FUT5 (0.38) | DTYMKPOLB | |
| SCHEMBL23734254 | 0.88 | FUT5 (0.38) | DTYMKPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | P2RX3 4623/4885P2RX1 4585/4885P2RX2 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.